The role of ghrelin in anorexia-cachexia syndromes
- PMID: 23601421
- DOI: 10.1016/B978-0-12-410473-0.00003-9
The role of ghrelin in anorexia-cachexia syndromes
Abstract
Anorexia, sarcopenia, and cachexia are common complications of many chronic conditions including cancer, rheumatoid arthritis, HIV infection, aging, and chronic lung, heart, or kidney disease. Currently, there is no effective treatment for muscle atrophy or wasting conditions although they typically take a significant toll on the quality of life of patients and are associated with poor prognosis and decreased survival. Ghrelin affects multiple key pathways in the regulation of body weight, body composition, and appetite in the setting of cachexia that may lead to an increase in appetite and growth hormone secretion and a reduction in energy expenditure and inflammation. The net effect is increased lean body mass and fat mass preservation. In this chapter, we review the mechanisms of action of ghrelin and present the available data in animal models and human trials using ghrelin or ghrelin mimetics in different settings of cachexia.
Copyright © 2013 Published by Elsevier Inc. Published by Elsevier Science & Technology.. All rights reserved.
Similar articles
-
Control of food intake and muscle wasting in cachexia.Int J Biochem Cell Biol. 2013 Oct;45(10):2179-85. doi: 10.1016/j.biocel.2013.07.016. Epub 2013 Jul 30. Int J Biochem Cell Biol. 2013. PMID: 23911307
-
Treatment of cachexia: melanocortin and ghrelin interventions.Vitam Horm. 2013;92:197-242. doi: 10.1016/B978-0-12-410473-0.00008-8. Vitam Horm. 2013. PMID: 23601426 Review.
-
Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.Cancer Treat Rev. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. Cancer Treat Rev. 2015. PMID: 26386985 Review.
-
Enhanced expressions of mRNA for neuropeptide Y and interleukin 1 beta in hypothalamic arcuate nuclei during adjuvant arthritis-induced anorexia in Lewis rats.Neuroimmunomodulation. 2009;16(6):377-84. doi: 10.1159/000228912. Epub 2009 Jul 17. Neuroimmunomodulation. 2009. PMID: 19609086
-
Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?Mol Cell Endocrinol. 2011 Jun 20;340(1):97-105. doi: 10.1016/j.mce.2011.02.012. Epub 2011 Feb 25. Mol Cell Endocrinol. 2011. PMID: 21354462 Free PMC article. Review.
Cited by
-
Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis.Nutrients. 2020 Apr 6;12(4):1006. doi: 10.3390/nu12041006. Nutrients. 2020. PMID: 32268520 Free PMC article. Clinical Trial.
-
Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.BMC Cancer. 2018 Nov 27;18(1):1174. doi: 10.1186/s12885-018-5080-4. BMC Cancer. 2018. PMID: 30482179 Free PMC article.
-
The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer.Curr Oncol Rep. 2020 May 15;22(6):54. doi: 10.1007/s11912-020-00916-9. Curr Oncol Rep. 2020. PMID: 32409907 Free PMC article. Review.
-
Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.Int J Mol Sci. 2018 Nov 5;19(11):3471. doi: 10.3390/ijms19113471. Int J Mol Sci. 2018. PMID: 30400622 Free PMC article. Review.
-
Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.Support Care Cancer. 2017 May;25(5):1651-1659. doi: 10.1007/s00520-016-3560-0. Epub 2017 Jan 10. Support Care Cancer. 2017. PMID: 28074289
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources